Anxiety and depression, key symptoms of the cocaine withdrawal syndrome in human addicts, are considered the main factors that precipitate relapse in chronic cocaine addiction. Preclinical studies have found that rodents exposed to different withdrawal periods show an increase in anxiety and depressive-like behavior. Mirtazapine – a tetracyclic medication – is used primarily to treat depression and, sometimes, anxiety. It has also successfully improved withdrawal symptoms in drug-dependent patients.
Aim:
This study sought to determine whether chronic dosing of mirtazapine during cocaine withdrawal reduced depression- and anxiety-like behaviors that characterize cocaine withdrawal in animals.
Methods:
Cocaine pre-treated Wistar rats were subjected to a 60-day cocaine withdrawal period during which depression- and anxiety-like behaviors were evaluated in open field tests (OFT), the elevated plus-maze (EPM), the light–dark box test (LDT), the forced swimming test (FST) and spontaneous locomotor activity (SLA).
Results:
We found that chronic dosing with different doses of mirtazapine (30 and 60 mg/kg) decreased depression- and anxiety-like behaviors induced by different doses of cocaine (10, 20 and 40 mg/kg) during the 60-day cocaine withdrawal.
Interpretation:
Our results suggest that the pharmacological effect of mirtazapine on its target sites of action (α2-adrenergic and 5-HT2A and 5-HT3 receptors) within the brain may improve depression- and anxiety-like behaviors for long periods.
Conclusion:
Therefore, the findings support the use of mirtazapine as a potentially effective therapy to reduce anxiety and depressive-like behavior during cocaine withdrawal.
AfsharMKnappCMSarid-SegalOet al. (2012) The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse38: 181–186.
2.
AnYChenCInoueTet al. (2016a) Mirtazapine exerts an anxiolytic-like effect through activation of the median raphe nucleus-dorsal hippocampal 5-HT pathway in contextual fear conditioning in rats. Prog Neuropsychopharmacol Biol Psychiatry70: 17–23.
3.
AnYInoueTKitaichiYet al. (2013) Anxiolytic-like effect of mirtazapine mediates its effect in the median raphe nucleus. Eur J Pharmacol720: 192-197.
4.
AnYInoueTKitaichiYet al. (2015) Subchronic lithium treatment increases the anxiolytic-like effect of mirtazapine on the expression of contextual conditioned fear. Eur J Pharmacol747: 13–17.
5.
AnYInoueTKitaichiYet al. (2016b) Combined treatment with subchronic lithium and acute intracerebral mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic-like effect synergistically. Eur J Pharmacol783: 112–116.
6.
AnkerJJCarrollME (2010) Reinstatement of cocaine seeking induced by drugs, cues, and stress in adolescent and adult rats. Psychopharmacology (Berl)208: 211–222.
7.
AraosPPedrazMSerranoAet al. (2015) Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: Influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol20: 756–772.
8.
AraosPVergara-MoraguesEPedrazMet al. (2014) Psychopathological comorbidity in cocaine users in outpatient treatment. Adicciones26: 15–26.
9.
BahiA (2016) Sustained lentiviral-mediated overexpression of microRNA124a in the dentate gyrus exacerbates anxiety- and autism-like behaviors associated with neonatal isolation in rats. Behav Brain Res311: 298–308.
10.
BahiAAl MansouriSAl MemariEet al. (2014a) β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol Behav135: 119–124.
11.
BahiASchwedJSWalterMet al. (2014b) Anxiolytic and antidepressant-like activities of the novel and potent non-imidazole histamine H₃ receptor antagonist ST-1283. Drug Des Devel Ther8: 627–637.
Barbosa-MéndezSMatus-OrtegaMFlores-ZamoraAet al. (2017b) Dose- and time-dependent effects of mirtazapine on the expression of cocaine-induced behavioral sensitization in rats. Psychiatry Res254: 301–310.
14.
BeckerJB (2016) Sex differences in addiction. Dialogues Clin Neurosci18: 395–402.
15.
BittoloTRaminelliCADeianaCet al. (2016) Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice. Sci Rep6: 19796.
16.
CalipariESBeveridgeTJJonesSRet al. (2013) Withdrawal from extended-access cocaine self-administration results in dysregulated functional activity and altered locomotor activity in rats. Eur J Neurosci38: 3749–3757.
17.
ChandrasekaranPK (2008) Employing mirtazapine to aid benzodiazepine withdrawal. Singapore Med J49: e166–e167.
18.
ChanrionBMannourylaCourCGavariniSet al. (2008) Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: Differential modulation of cell surface expression and signal transduction. Mol Pharmacol73: 748–757.
19.
CiprianiAFurukawaTASalantiGet al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet373: 746–758.
20.
ConwayKPComptonWStinsonFSet al. (2006) Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry67: 247–257.
21.
CorneliusJRDouaihyABClarkDBet al. (2012) Mirtazapine in comorbid major depression and alcohol dependence: An open-label trial. J. Dual Diagn8: 200-204.
22.
CorneliusJRDouaihyABClarkDBet al. (2013) Mirtazapine in comorbid major depression and alcohol use disorder: A long-term follow-up study. J Addict Behav Ther Rehabil3: 1560.
23.
CorneliusJRChungTDouaihyABet al. (2016) Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial. Psychiatry Res242: 326–330.
24.
CrawleyJGoodwinFK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav13:167–170.
25.
CroomKFPerryCMPloskerGL (2009) Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drugs23: 427–452.
26.
CryanJFPageMELuckiI (2005) Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl)182: 335–344.
27.
de BoerTH (1995) The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol10(Suppl 4): 19–23.
28.
de BoerTH (1996) The pharmacologic profile of Mirtazapine. J. Clin Psychiatry 57(Suppl 4): 19–25.
29.
de BoerTHNefkensFvan HelvoirtAet al. (1996) Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. J Pharmacol Exp Ther277: 852–860.
30.
de Oliveira Citó MdoCda SilvaFCSilvaMIet al. (2012) Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone and propranolol. Behav Brain Res231: 116–123.
31.
DrapierDBentué-FerrerDLaviolleBet al. (2007) Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res176: 202–209.
32.
DworkinSICoCSmithJE (1995) Rat brain neurotransmitter turnover rates altered during withdrawal from chronic cocaine administration. Brain Res682: 116–126.
33.
El-HageCRappeneauVEtievantAet al. (2012) Enhanced anxiety observed in cocaine withdrawn rats is associated with altered reactivity of the dorsomedial prefrontal cortex. PLoS One7: e43535.
34.
EngelDZomkowskiADLieberknechtVet al. (2013) Chronic administration of duloxetine and mirtazapine downregulates proapoptotic proteins and upregulates neurotrophin gene expression in the hippocampus and cerebral cortex of mice. J Psychiatr Res47:802–808.
35.
ErbSKayyaliHRomeroK (2006) A study of the lasting effects of cocaine pre-exposure on anxiety-like behaviors under baseline conditions and in response to central injections of corticotropin-releasing factor. Pharmacol Biochem Behav85: 206–213.
36.
FuchsRAEvansKAMehtaRHet al. (2005) Influence of sex and estrous cyclicity on conditioned cue-induced reinstatement of cocaine seeking behavior in rats. Psychopharmacology (Berl)179: 662–672.
37.
GambiFDe BerardisDCampanellaDet al. (2005) Mirtazapine treatment of generalized anxiety disorder: A fixed dose, open label study. J Psychopharmacol19: 483–487.
38.
GawinFH (1991) Cocaine addiction: Psychology and neurophysiology. Science251: 1580–1586.
39.
GawinFHKleberHD (1986) Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry43: 107–113.
40.
GoodnickPJPuigADeVaneCLet al. (1999) Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry60: 446–448.
41.
GrantBFSahaTDRuanWJet al. (2016) Epidemiology of DSM-5 drug use disorder: Results from the National Epidemiologic survey on alcohol and related conditions-III. JAMA Psychiatry73: 39–47.
42.
GrantBFStinsonFSDawsonDAet al. (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry61: 807–816.
43.
GrasmäderKVerwohltPLKühnKUet al. (2005) Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry38: 113–117.
44.
HashimotoTShiinaAHasegawaT (2016) Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: A pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial. Ann Gen Psychiatry19: 15: 27.
45.
HodesGEHill-SmithTELuckiI (2010) Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice. Neurosci Lett484: 12–16.
46.
HuzarskaMZielińskiMHermanZS (2006) Repeated treatment with antidepressants enhances dopamine D1 receptor gene expression in the rat brain. Eur J Pharmacol532: 208–213.
47.
JakubovskiEVarigondaALFreemantleNet al. (2016) Systematic review and meta-analysis: Dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry173: 174–183.
48.
KaminskaKRogozZ (2016) The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats. J Physiol Pharmacol67: 471–480.
49.
KamphuisJTaxisKSchuiling-VeningaCCet al. (2015) Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in The Netherlands. J Clin Psychopharmacol35: 468–470.
KampmanKMDackisCLynchKGet al. (2006) A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend85: 129–137.
52.
KampmanKMVolpicelliJRMulvaneyFet al. (2001b) Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend63: 69–78.
53.
KolcsarMGállZDogaruMT (2014) Dose dependent effects of serotonergic agents on anxiety. Acta Physiol Hung101: 479–487.
54.
Ladrón de Guevara-MirandaDMillónCRosell-ValleCet al. (2017) Long-lasting memory deficits in mice withdrawn from cocaine are concomitant with neuroadaptations in hippocampal basal activity, GABAergic interneurons and adult neurogenesis. Dis Model Mech10: 323–336.
55.
LaiHMClearyMSitharthanTet al. (2015) Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis. Drug Alcohol Depend154: 1–13.
56.
LandgrebeJWelzlGMetzTet al. (2002) Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J Psychiatr Res36:119–129.
57.
LapmaneeSCharoenphandhuJCharoenphandhuN (2013) Beneficial effects of fluoxetine, reboxetine, venlafaxine, and voluntary running exercise in stressed male rats with anxiety- and depression-like behaviors. Behav Brain Res250: 316–325.
58.
LapmaneeSCharoenphandhuNKrishnamraJet al. (2012) Anxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats. Behav Brain Res231: 20–28.
LiappasJPaparrigopoulosTTzavellasEet al. (2004) Alcohol detoxification and social anxiety symptoms: A preliminary study of the impact of mirtazapine administration. J Affect Disord76: 279–284.
61.
MatrejaPSBadyalDKDeswalRSet al. (2012) Efficacy and safety of add on low-dose mirtazapine in depression. Indian J Pharmacol44: 173–177.
62.
MillanMJ (2005) Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: Focus on novel therapeutic strategies. Therapie60: 441–460.
63.
MuguruzaCMiranda-AzpiazuPDíez-AlarciaRet al. (2014) Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment. Neuropharmacology86: 311–318.
64.
MuguruzaCRodríguezFRozasIet al. (2013) Antidepressant-like properties of three new α2-adrenoceptor antagonists. Neuropharmacology65: 13–19.
65.
NowakowskaEChoderaAKusK (1996) Anxiolytic and memory improving activity of fluoxetine. Pol J Pharmacol48: 255–260.
66.
OlivierJDVallèsAvan HeeschFet al. (2011) Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring. Psychopharmacology (Berl)217: 419–432.
67.
PaineTAJackmanSLOlmsteadMC (2002) Cocaine-induced anxiety: Alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol13: 511–523.
68.
PedrazMAraosPGarcía-MarchenaNet al. (2015a) Sex differences in psychiatric comorbidity and plasma biomarkers for cocaine addiction in abstinent cocaine-addicted subjects in outpatient settings. Front Psychiatry6: 17.
69.
PedrazMMartín-VelascoAIGarcía-MarchenaNet al. (2015b) Plasma concentrations of BDNF and IGF-1 in abstinent cocaine users with high prevalence of substance use disorders: Relationship to psychiatric comorbidity. PLoS One10: e0118610.
70.
PellowSChopinPFileSEet al. (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods14: 149–167.
71.
PellowSFileSE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat. Pharmacol Biochem Behav24: 525–529.
72.
PerrineSASheikhISNwaneshiuduCet al. (2008) Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat. Neuropharmacology54: 355–364.
73.
PorsoltRDBertinAJalfreM (1977a) Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther229: 327–336.
74.
PorsoltRDBertinAJalfreM (1978) “Behavioural despair” in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol51: 291–294.
75.
PorsoltRDBrossardGHautboisCet al. (2001) Rodent models of depression: Forced swimming and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci Chapter 8: Unit 8.10A.
76.
PorsoltRDLe PichonMJalfreM (1977b) Depression: A new animal model sensitive to antidepressant treatments. Nature266: 730–732.
77.
RénéricJPBouvardMStinusL (2002) In the rat forced swimming test, NA-system mediated interactions may prevent the 5-HT properties of some subacute antidepressant treatments being expressed. Eur Neuropsychopharmacol12:159–171.
78.
RobertGDrapierDBentué-FerrerDet al. (2011) Acute and chronic anxiogenic-like response to fluoxetine in rats in the elevated plus-maze: Modulation by stressful handling. Behav Brain Res220: 344–348.
79.
RogóżZ (2010) Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice. Pharmacol Rep62: 1191–1196.
80.
RogóżZ (2012) Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacol Rep64: 1567–1572.
81.
RogóżZKabzińskiM (2011a) Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacol Rep63: 1533–1538.
82.
RogóżZKabzińskiMSadajWet al. (2012) Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep64: 1391–1399.
83.
RogóżZKamińskaKPańczyszyn-TrzewikPet al. (2017) Repeated co-treatment with antidepressants and risperidone increases BDNF mRNA and protein levels in rats. Pharmacol Rep69: 885–893.
84.
RogóżZSkuzaG (2011b) Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacol Rep63: 1547–1552.
85.
RogóżZSkuzaGLegutkoB (2005) Repeated treatment with mirtazepine induces brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol56:661–671.
86.
RogóżZWróbelADlabogaDet al. (2002a) Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol54: 381–389.
87.
RogóżZWrobelADlabogaDet al. (2002b) Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol53: 105–116.
88.
RudoyCAVan-BockstaeleEJ (2007) Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry31: 1119–1129.
89.
Salazar-JuárezABarbosa-MéndezSJuradoNet al. (2016) Mirtazapine prevents induction and expression of cocaine-induced behavioral sensitization in rats. Prog Neuropsychopharmacol Biol Psychiatry68: 15–24.
90.
Salazar-JuárezABarbosa-MéndezSMerino-ReyesPet al. (2017) Chronic dosing with mirtazapine does not produce sedation in rats. Rev Bras Psiquiatr39: 228–236.
91.
SarnyaiZBíróEGardiJet al. (1995) Brain corticotropin-releasing factor mediates “anxiety-like” behavior induced by cocaine withdrawal in rats. Brain Res675: 89–97.
92.
SchuttersSIVan-MegenHJVan-VeenJFet al. (2010) Mirtazapine in generalized social anxiety disorder: A randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol25: 302–304.
93.
SlatteryDAMorrowJAHudsonALet al. (2005) Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology30: 1278–1287.
94.
SilvaMTAlvesCRSantaremEM (1999) Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze. Braz J Med Biol Res32: 333–339.
95.
SofuogluMDudish-PoulsenSBrownSBet al. (2003) Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend69: 273–282.
96.
SofuogluMDudish-PoulsenSPolingJet al. (2005) The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addict Behav30: 1125–1134.
97.
SofuogluMPolingJGonzalezGet al. (2006) Cocaine withdrawal symptoms predict medication response in cocaine users. Am J Drug Alcohol Abuse32: 617–627.
98.
StokerAKMarkouA (2011) Withdrawal from chronic cocaine administration induces deficits in brain reward function in C57BL/6J mice. Behav Brain Res223: 176–181.
99.
TsutsumiTSugawaraHItoRet al. (2016) Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder. Neuropsychiatr Dis Treat12: 2533–2538.
100.
UenoFNakajimaSSuzukiTet al. (2015) Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression. J Clin Psychiatry76: 434–439.
101.
VenkatasubramanianRKumarCNPandeyRS (2013) A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. J Affect Disord150: 644–648.
102.
WalshSLStoopsWWMoodyDEet al. (2009) Repeated dosing with oral cocaine in humans: Assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol17: 205–216.
103.
WatanbeNIchiroMONakagawaAet al. (2008) Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis. J Clin Psychiatry69: 1404–1415.
104.
WooHILimSWMyungWet al. (2018) Differentially expressed genes related to major depressive disorder and antidepressant response: Genome-wide gene expression analysis. Exp Mol Med50: 92.
105.
YangWHeHPanYet al. (2017) Cocaine withdrawal reduces gamma-aminobutyric acid-ergic transmission and gephyrin expression at medial prefrontal cortex in cocaine-conditioned place-preference rats, which shows increased cocaine seeking. Eur Addict Res23: 28–36.
